Severity Predictors of COVID-19 in SARS-CoV-2 Variant,

Delta and Omicron Period; Single Center Study

Fumihiro Ogawa, MD, PhD, Yasufumi Oi, MD, PhD, Hiroshi Honzawa, MD, Naho Misawa,

MD, Tomoaki Takeda, MD, Yuusuke Kikuchi, MD, Ryosuke Fukui, MD, Katsushi Tanaka,

MD, PhD, Daiki Kano, MD, Hideaki Kato, MD, PhD, Takeru Abe, MA, PhD, Ichiro

Takeuchi, MD, PhD

Department of Emergency Medicine, Yokohama City University, School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan

Fumihiro Ogawa; fumihiro@yokohama-cu.ac.jp

Yasufumi Oi; <u>yasu7azteca@ybb.ne.jp</u>

Hiroshi Honzawa: doubleh@yokohama-cu.ac.jp

Naho Misawa: mon_naho_mla@yahoo.co.jp

Tomoaki Takeda: magical@yokohama-cu.ac.jp

Yushi Kikuchi: yushimail.k1213@gmail.com

Ryosuke Fukui: Ryosuke.29119921005@gmail.com

Katsushi Tanaka: <u>t226043g@yokohama-cu.ac.jp</u>

Daiki Kano: swazxde2000@gmail.com

Hideaki Kato: ekato@yokohama-cu.ac.jp

Takeru Abe; <u>abet@yokohama-cu.ac.jp</u>

Ichiro Takeuchi; itake@myad.jp

*Corresponding author:

Fumihiro Ogawa, MD, PhD

Department of Emergency Medicine, Yokohama City University, School of Medicine

3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan

Phone: +81-45-787-2800 e-mail: fumihiro@yokohama-cu.ac.jp

Short Title:

Severity Predictors of COVID-19 in SARS-CoV-2 Variant

1 Abstract

2	Background: The outcomes of coronavirus disease 2019 (COVID-19) treatment have
3	improved due to vaccination and the establishment of better treatment regimens. However,
4	the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SARS-
5	CoV-2), which causes COVID-19, and the corresponding changes in the characteristics of the
6	disease present new challenges in patient management. This study aimed to analyze
7	predictors of COVID-19 severity caused by the delta and omicron variants of SARS-CoV-2.
8	Methods: We retrospectively analyzed the data of patients who were admitted for COVID-19
9	at Yokohama City University Hospital from August 2021 to March 2022.
10	Results: A total of 141 patients were included in this study. Of these, 91 had moderate
11	COVID-19, whereas 50 had severe COVID-19. There were significant differences in sex,
12	vaccination status, dyspnea, sore throat symptoms, and body mass index (BMI) (p <0.0001, p
13	<0.001, p $<$ 0.001, p=0.02, p $<$ 0.0001, respectively) between the moderate and severe
14	COVID-19 groups. Regarding comorbidities, smoking habit and renal dysfunction were
15	significantly different between the two groups (p=0.007 and p=0.01, respectively). Regarding
16	laboratory data, only LDH level on the first day of hospitalization was significantly different
17	between the two groups (p <0.001). Multiple logistic regression analysis revealed that time
18	from the onset of COVID-19 to hospitalization, BMI, smoking habit, and LDH level were
19	significantly different between the two groups (p<0.03, p=0.039, p=0.008, p<0.001,
20	respectively). The cut-off value for the time from onset of COVID-19 to hospitalization was
21	four days (sensitivity, 0.73; specificity, 0.70).
22	Conclusions: Time from the onset of COVID-19 to hospitalization is the most important
23	factor in the prevention of the aggravation of COVID-19 caused by the delta and omicron
24	SARS-CoV-2 variants. Appropriate medical management within four days after the onset of

- 25 COVID-19 is essential for preventing the progression of COVID-19, especially in patients
- with smoking habits.
- 27 Keywords: COVID-19, Variant, Delta, Omicron, Severity, Predictor

28 Introduction

52

29	The coronavirus disease 2019 (COVID-19) pandemic has caused a significant
30	increase in hospitalizations for pneumonia with multiorgan disease. COVID-19 is caused by
31	the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccines and
32	treatment methods against SARS-CoV-2 are increasingly being developed worldwide.
33	Although the number of patients with COVID-19 is still high, these measures have led to the
34	reduction of disease severity and improvement of prognosis after the onset of symptoms.
35	However, despite tremendous efforts by scientists, researchers, and health practitioners to
36	combat the COVID-19 pandemic, the emergence of new variants of SARS-CoV-2 present
37	new challenges in patient management. As the development of vaccines and treatments
38	progresses and patient outcomes improve, SARS-CoV-2 repeatedly mutates and tries to
39	survive these improved therapies. The World Health Organization and Centers for Disease
40	Control and Prevention have identified the alpha, beta, gamma, delta, epsilon, eta, lota, kappa,
41	mu, zeta, and omicron variants of SARS-CoV-2 [1, 2]. The recently identified delta and
42	omicron variants are both highly infectious and are different from the previous strains in
43	terms of infectivity, severity, and clinical symptoms. Thus, retrospective analysis of the
44	characteristics and aggravation markers of patients newly infected with the delta and omicron
45	variants of SARS-CoV-2 is essential and will lay the groundwork for the management of the
46	emergence of new mutant strains of SARS-CoV-2. Therefore, this study aimed to analyze
47	and describe the characteristics, clinical features, and outcomes of COVID-19 caused by the
48	delta and omicron variants of SARS-CoV-2 according to disease severity.
49	
50	
51	
50	

53 **Patients and methods**

54	This was a retrospective study conducted using the data of patients with COVID-19
55	(except for outpatients with mild COVID-19) who underwent standard treatment, including
56	intensive care, at Yokohama City University Hospital from June 2021 to March 2022. The
57	clinical and biological features of the patients were analyzed. During the observation period,
58	June 2021 to December 2021 and January 2022 to March 2022 were marked by a surge in the
59	number of infections caused by the delta and omicron variants of SARS-CoV-2, respectively.
60	Thus, we defined June 2021 to December 2021 as the 'delta period' and January 2022 to
61	March 2022 as the 'omicron period.' If a patient with mild COVID-19 had a severe risk
62	factor, such as old age, chronic kidney disease that requires hemodialysis, or severe
63	immunosuppression, we judged the patient's condition and COVID-19 severity and decided
64	on hospitalization. The characteristics, risk factors, morbidity, and mortality outcomes of the
65	patients were analyzed as well. Information on comorbidities were obtained for each patient,
66	and outcome data were obtained during follow-up in our hospital.
67	This study was approved by the Ethics Committee of the Yokohama City University
68	School of Medicine. Written informed consent was obtained from each patient or their family

69 members before treatment.

70 Classification of coronavirus disease severity

Disease severity was categorized into the mild-moderate stage (moderate group) and the severe-critical stage (severe group) based on previously published guidelines on the diagnosis and treatment of COVID-19 [3]. Mild cases were defined as patients with no symptoms, no need for oxygen, and no sign of pneumonia on computed tomography (CT) scans. Moderate cases were defined as patients with mild respiratory symptoms, radiological evidence of pneumonia, and oxygen saturation (SpO₂) >93% and <96%. Severe cases were

defined as patients with SpO₂ \leq 94% and requiring oxygen support. Critical cases were

78 defined as patients that required heart–lung machine or extracorporeal membrane

79 oxygenation (ECMO) support for acute respiratory distress syndrome (ARDS). Severe and

80 critical cases were combined into the same group in this study. We did not consider CT score

81 [4, 5] in the classification of COVID-19 severity.

82 Sample collection

83 The blood samples of the patients were collected at admission depending on the 84 clinical conditions of the patients with severe COVID-19 who needed oxygen and those in 85 critical conditions who needed intubation management. Table 1 shows the severity 86 classification and treatment strategies for the patients with critical COVID-19. On admission 87 to our hospital, COVID-19 was diagnosed using a positive reverse transcriptase-polymerase 88 chain reaction (RT-PCR) assay for SARS-CoV-2. The RT-PCR assay was performed using 89 respiratory tract and laryngeal swab samples, which were sent to a designated diagnostic 90 laboratory. Standard procedures for sample collection were used to ensure that all the 91 samples were treated rapidly and equally.

92 Data collection

93 Patients were followed up until hospital discharge or death. The patient information collected

94 included demographic characteristics, pre-existing comorbidities on the date of

95 hospitalization, and laboratory test results. The laboratory tests included measurement of

96 several hemostatic biomarkers, such as white blood cell count (WBC) and D-dimer, C-

97 reactive protein (CRP), aspartate aminotransferase (AST), alanine aminotransferase (ALT),

98 lactate dehydrogenase (LDH), blood urea nitrogen (BUN), creatinine (Cre), total bilirubin

99 (T.bil), and interleukin-6 (IL-6) levels, which have been reported to be severity markers of

100 COVID-19. These biomarker levels measured from the day of admission to the day of

101 discharge depending on the patient's condition.

We recorded the clinical interventions administered during the observation period,
including the use of antibiotics, antiviral agents, systemic corticosteroids, vasoactive
medications, venous thromboembolism prophylaxis, antiplatelet or anticoagulation treatment,
renal replacement therapy, high-flow oxygen therapy, and mechanical ventilation (invasive
and noninvasive).

107 **Statistical analysis**

108 Patients were divided into two groups for comparison: the moderate group and the 109 severe group. For each group, medians (interquartile ranges) and frequencies (%) were 110 reported for continuous and categorical variables, respectively. We used the Mann-Whitney 111 U test for analysis of continuous variables and Fisher's exact test for the evaluation of 112 categorical variables. Patient characteristics, time from the onset of COVID-19 or acquisition 113 of a positive PCR result to hospitalization, results of standard blood tests, and physical 114 condition were analyzed. In addition, repeated measures analyses of variance was used to 115 evaluate group and time differences, as well as their interactions, for WBC and D-dimer, 116 CRP, AST, ALT, LDH, BUN, Cre, T.bil, and IL-6 levels. We utilized a multivariable logistic 117 regression model to identify the relationship between COVID-19 severity and patient 118 characteristics, including primary symptoms, comorbidities, and laboratory data. In addition, 119 to determine an optimal cut-off value of the interval between onset and admission for 120 different periods of COVID-19 variants, the receiver operating curve, ROC, analysis was 121 performed. The area under the curve, AUC, sensitivity, specificity, and their 95% confidence 122 interval were calculated. Two-sided P values < 0.05 were considered statistically significant. 123 All statistics analyses were conducted using JMP Pro Version 15 (SAS Institute Inc., Cary, 124 NC, USA) and IBM SPSS Statistics for Windows, Version 25.0 (Armonk, NY: IBM Corp). 125

127 **Results**

128	We analyzed 141 patients with COVID-19 (median age, 59.6 [IQR, 56-62] years)
129	who required hospitalization and were admitted to our hospital during the study period.
130	Baseline demographic characteristics, sex, age, time from onset of COVID-19 to
131	hospitalization, primary symptoms, physical characteristics, smoking habits, vaccination
132	status, and comorbidities of the patients are reported in Table 2. Characteristics of patients
133	admitted during the delta and omicron periods are summarized in Supplemental Table 1. The
134	data showed significant differences in patients' age, time from onset to hospitalization,
135	dyspnea as a primary symptom, weight, body mass index (BMI), cardiac disease, renal
136	dysfunction, continuous hemodialysis, and hypertension as comorbidities between the two
137	periods (p<0.001, p<0.0001, p=0.03, p=0.027, p=0.024, p<0.0001, p=0.0003, p=0.01, and
138	p=0.0027, respectively). The major difference between the delta and omicron periods was
139	believed to be attributable the effect of vaccination on the public.

140 Classification of coronavirus disease severity

141 Of the 141 patients analyzed in this study, 91 had moderate COVID-19 and did not 142 need intensive care, whereas 50 had severe COVID-19 and needed mechanical ventilation. 143 The characteristics, primary symptoms, comorbidities, and primary laboratory data of the 144 patients classified according to COVID-19 severity are shown in Table 3. There was no 145 significant difference in age between the moderate group $(59\pm17.5 \text{ years}; \text{ range}, 19-93 \text{ years})$ 146 and the severe group $(57\pm13.3 \text{ years}; \text{ range}, 30-93 \text{ years})$ (p=0.31). Male patients were more 147 likely to progress to severe COVID-19 than were female patients (p=0.0006). Time from the 148 onset of COVID-19 symptoms to the day of hospitalization was significantly longer in the 149 severe group than in the moderate group (moderate group: 3±3.6 days; range, 0-13 days vs. 150 severe group: 8±4.2 days; range, 0-22 days) (p<0.0001). However, there was no significant

151	difference between the two groups in terms of the time from the acquisition of a positive PCR
152	test result to hospitalization (moderate group: 1±2.3 days; range, 0-13 days vs. severe group:
153	2±2.3 days, range, 0-10 days) (p=0.06). Regarding primary symptoms, there was a significant
154	difference in the frequency of dyspnea between the two groups (p<0.0001). Regarding
155	physical features, patients in the severe group generally had a greater body weight (59.9±16.0
156	kg vs. 74.1±16.5 kg) and higher BMI (22.8±10.8 vs. 26.3±8.0) than those in the moderate
157	group (p<0.0001 and p=0.0001, respectively). Smoking habit was significantly different
158	between the two groups (p=0.007). No significant frequency of any comorbidity was
159	observed in the severe group. However, renal disease was significantly more frequent in the
160	moderate group than in the severe group (p=0.016).
161	Regarding laboratory data on the day of admission, there were significant differences
162	in AST (34.0±40.2 IU/l vs. 50.5±46.9 IU/l), ALT (21.0±30.0 IU/l vs. 50.5±41.3 IU/l), and
163	LDH (300.0 ± 136.7 IU/l vs. 499.5 ± 192.1 IU/l) levels between the severe and moderate groups
164	(p<0.0001, p<0.0001, and p<0.0001, respectively). However, differences in IL-6 (52.3±121.7
165	pg/ml vs. 31.3±75.3 pg/ml), CRP (5.7±6.8 mg/dl vs. 6.4±7.5 mg/dl), and D-dimer (1.2±13.2
166	μ g/ml vs. 1.1 \pm 9.6 μ g/ml) levels between the two groups were not statistically significant
167	(p=0.16, p=0.2, and p=0.85, respectively).
168	Table 4 shows therapeutic strategies implemented for the treatment of the cases of
169	moderate and severe COVID-19. There was a significant difference between the moderate
170	and severe groups in terms of oxygen demand and intensive care beyond ventilator
171	management. In addition, there was a significant difference between the two groups in terms
172	of the characteristics of each treatment.
173	The above-mentioned results regarding the characteristics and clinical features of the

The above-mentioned results regarding the characteristics and clinical features of the moderate and severe groups, as well as the clinical characteristics of the patients admitted during the delta and omicron periods stratified according to disease severity, are outlined in

- 176 Supplemental Table 2. The greatest difference between the delta and omicron periods was the
- 177 difference in the spread of vaccination. Thus, there were some significant differences in
- 178 vaccination-associated factors between the two periods.

179 Multivariable logistic regression analysis

- 180 Multivariable logistic regression analysis was performed to identify the relationship
- 181 between COVID-19 severity and patient characteristics, including primary symptoms,
- 182 comorbidities, and laboratory data. The results showed that time from the onset of COVID-19
- 183 to hospitalization, BMI, smoking habits, and LDH level were significantly associated with
- 184 the COVID-19 severity (OR=1.16, p=0.026; OR=1.10, p=0.039; OR=3.70, p=0.008; and
- 185 OR=1.01, p< 0.001, respectively) (Table 5). The ROC curve (Fig. 1) showed that the time
- 186 from the onset of COVID-19 to hospitalization is an important factor associated with the
- 187 COVID-19 severity (AUC, 0.77 [95%CI, 0.69-0.84]; sensitivity, 0.73 [95%CI, 0.59-0.84];
- specificity, 0.70 [0.59-0.79]). The ROC also showed that the cut-off value for the time from
- 189 the onset of COVID-19 to hospitalization was four days.

190 **Discussion**

191	In this single-center retrospective study, we analyzed the characteristics, clinical
192	features, and outcomes of COVID-19 caused by the delta and omicron variants of SARS-
193	CoV-2 according to disease severity. The authors of previous reports [6, 7] have suggested
194	that the hyperactivation of the inflammatory cascade, leading to a cytokine storm, is a critical
195	biological response in patients with severe COVID-19. In addition, D-dimer, LDH, and CRP
196	levels are reported to be potential biomarkers for COVID-19 severity [6, 7]. Significantly
197	elevated levels of inflammatory cytokines TNF- α , IL-1, IL-6, and IL-10 have been
198	documented in cases of severe COVID-19 compared to cases of non-severe disease [8-12]. In
199	the present study, we did not focus on the levels of inflammatory cytokines for the
200	classification of COVID-19 severity. The present results showed that LDH, which is reported
201	to be a predictive biomarker for the aggravation of COVID-19 caused by the original variant
202	of SARS-CoV-2, is involved in the aggravation of COVID-19 caused by the delta and
203	omicron variants. Abnormalities in the levels of markers of cellular injury, particularly
204	elevated LDH level, have been linked to greater disease severity [13, 14]. Data from recent
205	studies suggest that LDH may be related to respiratory function and could be an important
206	predictor of respiratory failure in patients with COVID-19 [15]. On the contrary, the present
207	results indicated that IL-6, which has received considerable attention as a biomarker of the
208	progression of COVID-19, is not a predictive factor for the aggravation of COVID-19. It has
209	been reported [16-18] that SARS-CoV-2 infection increases the level of the inflammatory
210	cytokine IL-6, which is believed to cause multiple organ damage. Therefore, administration
211	of an IL-6 inhibitor has been established as a therapeutic strategy for COVID-19. However,
212	as the IL-6 levels of the patients in the present study were not significantly high, even in the
213	severe group, it could be concluded that IL-6 inhibitors may not be effective against COVID-
214	19. The possible reasons for the lack of significant increase in IL-6 levels in the severe group

215	are as follows: 1) the delta and omicron variants of SARS-CoV-2 could be less toxic than the
216	original variant due to mutations, 2) SARS-CoV-2 may have mutated to induce inflammatory
217	cytokines other than IL-6, and 3) IL-6 may not completely respond to SARS-CoV-2 infection
218	due to the effect of vaccination. However, since vaccination was not yet widespread during
219	the delta period, its effect may not have been extensive. In addition, since IL-6 level was
220	measured on the first day of hospitalization in this study, it is unlikely that it was affected by
221	the therapeutic drug administered. Thus, although we considered that various factors may be
222	responsible for the lack of significant increase in IL-6 levels, the influence of the mutation of
223	SARS-CoV-2 may be large. Furthermore, the lack of a significant increase in CRP and D-
224	dimer levels was also considered to be due to the mutation of the virus.
225	It has been reported that cardiovascular disease, chronic renal disease, chronic lung
226	diseases, diabetes mellitus, hypertension, immunosuppression, obesity, malignant tumor, and
227	sickle cell disease are prognostic factors of COVID-19 severity [13, 19-22]. We investigated
228	these comorbidities in the present study and found that except for obesity, there were no
229	significant differences between the comorbidities of the patients in the moderate and severe
230	COVID-19 groups. However, significantly more patients with moderate COVID-19 had
231	chronic renal failure than those with severe COVID-19. The reason for this finding is that it
232	was difficult for patients to receive medical treatment in the outpatient dialysis clinic because
233	chronic renal failure is one of the risk factors for aggravation of COVID-19. Regarding
234	obesity, BMI >30, which is a proxy for obesity, was considered a strong predictor in a
235	previous report [22]. There was a significant difference in BMI between the moderate and
236	severe groups in the present study. During the delta period, patients with a high BMI
237	developed more severe COVID-19. In addition, it was extremely difficult to manage their
238	systemic conditions using mechanical ventilation, prone position therapy, and ECMO.
239	However, BMI was considered to be slightly associated with COVID-19 severity during the

240 omicron period. It has been suggested that the effect of the COVID-19 vaccine may

241 contribute to the prevention of aggravation in patients with a high BMI.

242 In this study, we analyzed diabetes mellitus and glycated hemoglobin level, which 243 have been reported to be linked to inflammation, hypercoagulation, and high mortality 244 (27.7%) [23], and found no significant differences between the moderate and severe groups. 245 Therefore, abnormal glucose tolerance was not a predictor of aggravation in this study. 246 Regarding the time from the onset of COVID-19 to hospitalization, most patients felt 247 some symptoms of COVID-19, such as fever, sore throat, and fatigue, and rested while 248 waiting for recovery of their physical condition. In such a scenario, the respiratory status of 249 the patient gradually worsens and the disease severity progresses. This is because after 250 SARS-CoV-2 infection is established, the patient's respiratory condition gradually 251 deteriorates and the patient is placed in a condition in which breathing is not difficult, even in 252 a hypoxic state. This condition is called 'happy hypoxia' and is considered to be a precursor 253 to the deterioration of respiratory function. This respiratory disorder caused by excessive 254 spontaneous breathing without ventilator management is called patient self-inflated lung 255 injury (P-SILI). This concept was previously described [24, 25] as a possible interplay 256 between ventilation, surfactant dysfunction, and atelectasis during spontaneous ventilation, 257 which leads to ventilation-induced lung injury. In clinical settings, intravenous injection of 258 small doses of endotoxin in humans has a strong effect on respiratory drive, independent of 259 fever or symptoms [26]. In addition, some patients without any pre-existing lung injury 260 develop lung injury associated with hyperventilation [27]. Thus, in some patients, lung injury 261 due to increased tidal volumes and ventilation may occur during spontaneous breathing, 262 initiated by a high respiratory drive, which, in turn, leads to the development of lesions that 263 appear similar to the ventilator-induced lung injury (VILI) observed in mechanically 264 ventilated subjects. In these patients, the large spontaneous tidal volumes may be viewed as

265	the cause of injury. Hence, any therapy that minimizes the generation of these large tidal
266	volumes should be viewed as a prophylactic therapy against the progression of lung injury.
267	Considering the above-mentioned concept, if a spontaneously breathing patient has a high
268	respiratory drive that leads to increased minute ventilation with high tidal volumes, the goal
269	of therapy must be to minimize P-SILI. If the patient engages in spontaneous breathing based
270	on self-judgement, some parameters, such as changes in spontaneous breathing styles,
271	tachypnea, changes in respiratory patterns, and oxygen demand, should be strictly managed,
272	and any changes should be addressed immediately. If the changes are not managed
273	immediately, the condition of the patient may become more severe. It is important to
274	ascertain whether a spontaneously breathing patient has a high respiratory drive and has
275	adopted a ventilatory pattern that will lead to subsequent lung injury. This concept is
276	important for the management of respiratory conditions under mechanical ventilation for
277	patients with severe COVID-19. The specific time from the onset of COVID-19 to
278	aggravation and how long the deterioration of respiratory status should be observed have not
279	been reported in any previous study. In the present study, the ROC showed that the optimal
280	time from the onset of COVID-19 to hospitalization is four days. In other words, it is highly
281	likely that COVID-19 will progress to severe if a patient's respiratory status is altered within
282	four days after the onset of COVID-19, even if the patient is receiving home care; thus,
283	immediate intervention is required. Proper intubation and a lung-protective ventilatory
284	strategy guided by the severity of lung injury, including elevations in dead space, may be the
285	easiest and most efficient way to achieve this goal. It is possible that by applying the same
286	principles, mechanical ventilation can be administered "prophylactically or early" to protect
287	the lung from P-SILI. As such, under defined conditions, mechanical ventilation, far from
288	being just supportive or even damaging, becomes a true preventive measure against the
289	progression of lung injury and perhaps ARDS. ECMO is another method that can be used to

290 prevent P-SILI. When ventilator management for patients with severe COVID-19 reaches its 291 limits, introduction of ECMO as a lung protection strategy may be expected for the 292 prevention of or recovery from ARDS. However, regarding the introduction of ECMO, 293 systemic management is necessary for weighing the possibility of the occurrence of serious 294 complications caused by ECMO. 295 This study had several limitations. First, this was a single-center retrospective study 296 performed in one of the leading hospitals in Japan, which has generally accepted and treated 297 a large number of severely ill COVID-19 patients since the outbreak of disease. Unlike some 298 countries, few hospitals in Japan collectively treat patients with COVID-19. Patients with 299 COVID-19 are dispersed to nearby hospitals for treatment; thus, a single hospital does not 300 treat many cases. Second, the moderate COVID-19 group in this study included elderly 301 patients who did not need hospitalization for COVID-19 but could not stay alone at home due 302 to lack of assistance from a caregiver. In addition, the moderate COVID-19 group included 303 patients with mild COVID-19 who had several comorbidities and risk factors or patients who 304 were hospitalized for the treatment of other illnesses but incidentally tested positive for 305 COVID-19 without showing any symptoms. Thus, there may be some bias in our clinical 306 data. Third, we did not establish exclusion criteria for this study and excluded patients 307 undergoing treatment for other diseases to ensure that only the severity predictors of COVID-308 19 are considered. However, considering the spread of COVID-19 worldwide, the high 309 infectivity of SARS-CoV-2, and the severity of patient symptoms, we analyzed the severity 310 predictors without setting any exclusion criteria. Finally, this study focused on the 311 identification of predictors of the aggravation of COVID-19 using information available in 312 routine practice, results of measurable specimen testing, and data on patient management 313 based on standard of care. Combining these with the analysis of results of more advanced 314 examinations and diagnostic imaging tests should further narrow down the severity predictors.

315	However, although this may be possible for progressive research institutes, such as advanced
316	medical institutions and universities, we believed that it was more important to distinguish
317	COVID-19 severity in general medical institutions considering the spread of COVID-19
318	worldwide. The predictors identified this study, including the time from the onset of COVID-
319	19 to hospitalization, LDH level at hospitalization, BMI, and smoking habits, are easy to
320	understand and can be measured at any facility.
321	
322	Conclusion
323	This study showed that the time from the onset of COVID-19 to hospitalization is the
324	most important factor in the prevention of the aggravation of COVID-19 caused by the delta
325	and omicron variants of SARS-CoV-2. To prevent the aggravation of COVID-19, it is
326	necessary to initiate appropriate medical management within four days after the onset of

COVID-19, especially in patients with smoking habits, high BMI, and elevated LDH levels.

These findings may facilitate preparations for the next wave of COVID-19 caused by other

327

328

329

possible variants of SARS-CoV-2.

330 Acknowledgements

331	We would like to th	aml, ann a alla a ann a	in Domonton and of	Emperance N/	fadiaina and
111	we wonio nke io in	анк онг сонеауне	s in Department of	Emergency v	ieoncine and
001	ne noula line to th	unit our concugue.	s in Department of	Entergeney In	ieurenne una

- 332 clinical nurses in the intensive care unit of Yokohama City University Hospital and
- 333 Yokohama City University Medical Center Hospital for their kind assistance. And, we would
- like to thank Editage (www.editage.com) for English language editing.

335

336 **Declarations**

- 337 Ethical approval to report this case was obtained from Yokohama City University
- 338 Hospital (No.B200200048).

339

340 **Consent for publication**

341 Written consent was obtained from patients for the publication of this case report and

342 the relevant images. A copy of the written consent is available for review by the Editor-in-

343 Chief of PLOS One

344

345 Availability of data and materials

346 Data requests should be made to the corresponding authors.

347

348 Informed Consent

349 Written informed consent was obtained from the patients for their anonymized information to

350 be published in this article.

351

352 Funding

353 This study was not supported by any funding.

354

355 **Competing interests**

- 356 The authors declare that there are no conflicts of interest regarding the publication of this
- 357 paper.
- 358

359 Authors' contributions

- 360 FO prepared the manuscript and collected the references. IT coordinated the authors. FO, YO,
- 361 HH, NM, TT, YK, RF, KT, DK and HK provided clinical support. TA helped to draft the
- 362 manuscript. All authors have read and approved the final manuscript.

363 **References**

364	1.	World Health Organization. Tracking SARS-CoV-2 Variants [cited 2022 Jul 21].
365		Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants
366	2.	Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and
367		Definitions. 2022 Apr 26 [cited 2022 Jun 21]. Available from:
368		https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html
369	3.	Gandhi RT, Lynch JB, Del Rio C. Mild or moderate COVID-19. N Engl J Med.
370		2020;383: 1757-1766.
371	4.	Yuyun X, Lexi Y, Haochu W, Zhenyu S, Xiangyang G. Early warning information
372		for severe and critical patients with COVID-19 Based on quantitative CT analysis of
373		lung segments. Front Public Health. 2021; 9: 596938.
374	5.	Zhou S, Zhu T, Wang Y, Xia L. Imaging features and evolution on CT in 100
375		COVID-19 pneumonia patients in Wuhan, China. Eur Radiol. 2020;30: 5446-5454.
376	6.	Ayanian S, Reyes J, Lynn L, Teufel K. The association between biomarkers and
377		clinical outcomes in novel coronavirus pneumonia in a US cohort. Biomark Med.
378		2020;14: 1091-1097.
379	7.	Nakajima K, Abe T, Saji R, Ogawa F, Taniguchi H, Yamaguchi K, et al. Serum
380		cholinesterase associated with COVID-19 pneumonia severity and mortality. J Infect.
381		2021;82: 282-327.
382	8.	Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical features of
383		29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za
384		Zhi. 2020;43: E005.
385	9.	Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in
386		patients with COVID-19. Lancet Haematol. 2020;7: e438-e440.
387	10.	Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to
388		COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive
389		Care Med. 2020;46: 846-848.
390	11.	Wang W, Liu X, Wu S, Chen S, Li Y, Nong L, et al. Definition and risks of cytokine
391		release syndrome in 11 critically ill COVID-19 patients with pneumonia: Analysis of
392		disease characteristics. J Infect Dis. 2020;222:1444-1451.
393	12.	Sugiyama M, Kinoshita N, Ide S, Nomoto H, Nakamoto T, Saito S, et al. Serum
394		CCL17 level becomes a predictive marker to distinguish between mild/moderate and
395		severe/critical disease in patients with COVID-19. Gene. 2021;766: 145145.
396	13.	Cecconi M, Piovani D, Brunetta E, Aghemo A, Greco M, Ciccarelli M, et al. Early
397		predictors of clinical deterioration in a cohort of 239 patients hospitalized for
398		COVID-19 infection in Lombardy, Italy. J Clin Med. 2020;9: 1548
399	14.	Li Q, Cao Y, Chen L, Wu D, Yu J, Wang H, et al. Hematological features of persons
400		with COVID-19. Leukemia. 2020;34: 2163-2172.
401	15.	Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, et al. Lactate
402		dehydrogenase and C-reactive protein as predictors of respiratory failure in COVID-
403		19 patients. Clin Chim Acta. 2020; 509:135-138.
404	16.	Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for
405		coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J
406		Autoimmun. 2020;111: 102452.
407	17.	Tharmarajah E, Buazon A, Patel V, Hannah JR, Adas M, Allen VB, et al. IL-6
408		inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. J
409		Infect. 2021;82: 178-185.

410	18. Tasoudis PT, Arvaniti CK, Adamou AT, Belios I, Stone JH, Horick N, et al.
411	Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual
412	patient data meta-analysis from randomized controlled trials. Eur J Intern Med. 2022;
413	101: 41-48.
414	19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
415	mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort
416	study. Lancet. 2020;395: 1054-1062.
417	20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
418	infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395: 497-506.
419	21. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of
420	113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ.
421	2020;368: m1091.
422	22. Centers for Disease Control and Prevention. People with certain medical conditions.
423	2022 May 2 [cited 2022 Jun 21]. Available from:
424	https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-
425	medical-
426	conditions.html?%20CDC AA refVal=https%3A%2F%2Fwww.cdc.gov%2Fcorona
427	virus%%202F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-
428	<u>risk.%20html</u> .
429	23. Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic
430	inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res
431	Clin Pract. 2020;164: 108214.
432	24. Yoshida T, Fujino Y, Amato MB, Kavanagh BP. Fifty years of research in ARDS.
433	Spontaneous breathing during mechanical ventilation. Risks, mechanisms, and
434	management. Am J Respir Crit Care Med. 2017;195: 985-992.
435	25. Albert RK. The role of ventilation-induced surfactant dysfunction and atelectasis in
436	causing acute respiratory distress syndrome. Am J Respir Crit Care Med. 2012;185:
437	702-708.
438	26. Preas HL, Jubran A, Vandivier RW, Reda D, Godin PJ, Banks SM, et al. Effect of
439	endotoxin on ventilation and breath variability: role of cyclooxygenase pathway. Am
440	J Respir Crit Care Med. 2001;164: 620-626.
441	27. Brun-Buisson CJ, Bonnet F, Bergeret S, Lemaire F, Rapin M. Recurrent high-
442	permeability pulmonary edema associated with diabetic ketoacidosis. Crit Care Med.
443	1985;13: 55-56

444 Figure legends

- 445 **Figure 1**. Receiver Operatorating Characteristic of the period from onset to hospitalization
- related to severity of COVID-19 with area under the curve 0.77, sensitivity 0.73, specificity
- 447 0.70. From the ROC, the cut-off value of the period from onset of COVID-19 to
- 448 hospitalization was 4 days.

